Joseph Abi Jaoude
Overview
Explore the profile of Joseph Abi Jaoude including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sherry A, Msaouel P, Lin T, Abi Jaoude J, Kouzy R, Beck E, et al.
BMJ Oncol
. 2025 Jan;
3(1):e000322.
PMID: 39886131
Objective: Estimations of the treatment effect on overall survival (OS) may be influenced by post-progression therapies (PPTs). It is unclear how often OS analyses account for PPT effects. The purpose...
2.
Sherry A, Liu Y, Msaouel P, Lin T, Koong A, Lin C, et al.
medRxiv
. 2025 Jan;
PMID: 39867397
Background: Statistical significance currently defines superiority in phase III oncology trials. However, this practice is increasingly questioned. Here, we estimated the fragility of phase III oncology trials. Methods: Using Kaplan-Meier...
3.
Miller A, Passy A, Sherry A, Kouzy R, Abi Jaoude J, Lin T, et al.
JCO Oncol Pract
. 2025 Jan;
OP2400735.
PMID: 39778122
Purpose: This study aimed to determine complete toxicity reporting (CTR), and the use of subjective toxicity-minimizing language (TML) among phase III oncology trials. Methods: Two-arm superiority-design phase III oncology trials...
4.
Kleber T, Sherry A, Arifin A, Kupferman G, Kouzy R, Abi Jaoude J, et al.
J Natl Cancer Inst
. 2024 Dec;
PMID: 39657246
Background: Noninferiority (NI) and equivalence trials evaluate whether an experimental therapy's effect on the primary endpoint (PEP) is contained within an acceptable margin compared to standard-of-care. The reliability and impact...
5.
Sherry A, Lin T, McCaw Z, Beck E, Kouzy R, Abi Jaoude J, et al.
Int J Radiat Oncol Biol Phys
. 2024 Oct;
120(5):1239-1244.
PMID: 39352322
Purpose: Increasing data suggest that radiation therapy, particularly ablative radiation therapy, alters the natural history of metastatic disease. For patients with metastatic disease enrolled in prospective trials testing systemic therapy,...
6.
Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology
Sherry A, Msaouel P, Kupferman G, Lin T, Abi Jaoude J, Kouzy R, et al.
JCO Precis Oncol
. 2024 Sep;
8:e2400363.
PMID: 39348660
Purpose: The primary results of phase III oncology trials may be challenging to interpret, given that results are generally based on value thresholds. The probability of whether a treatment is...
7.
Sherry A, Passy A, McCaw Z, Abi Jaoude J, Lin T, Kouzy R, et al.
JCO Clin Cancer Inform
. 2024 Aug;
8:e2400102.
PMID: 39213473
Purpose: A previous study demonstrated that power against the (unobserved) true effect for the primary end point (PEP) of most phase III oncology trials is low, suggesting an increased risk...
8.
Sherry A, Lin T, McCaw Z, Beck E, Kouzy R, Abi Jaoude J, et al.
Int J Cancer
. 2024 Aug;
155(11):1939-1943.
PMID: 39138841
Disease progression in clinical trials is commonly defined by radiologic measures. However, clinical progression may be more meaningful to patients, may occur even when radiologic criteria for progression are not...
9.
Lin T, McCaw Z, Koong A, Lin C, Abi Jaoude J, Patel R, et al.
Clin Cancer Res
. 2024 Aug;
30(20):4791-4799.
PMID: 39133081
Purpose: Survival analyses of novel agents with long-term responders often exhibit differential hazard rates over time. Such proportional hazards violations (PHV) may reduce the power of the log-rank test and...
10.
Sherry A, Msaouel P, Kupferman G, Lin T, Abi Jaoude J, Kouzy R, et al.
medRxiv
. 2024 Aug;
PMID: 39108512
Most oncology trials define superiority of an experimental therapy compared to a control therapy according to frequentist significance thresholds, which are widely misinterpreted. Posterior probability distributions computed by Bayesian inference...